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Abstract
Background: Pre-clinical studies suggest that metformin and statins may delay pros-
tate cancer (PCa) metastases; however, data in humans are limited. To the best of our 
knowledge, this is the first human study aimed to quantify the individual and joint 
effects of statin and metformin use among patients with high-risk PCa.
Methods: This population-based retrospective cohort study identified patients from 
the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. 
Exposure to metformin and statins was ascertained from Medicare Prescription Drug 
Event files. The association with all-cause and PCa mortality were evaluated using 
Cox proportional hazard model with competing causes of death, where propensity 
scores were used to adjusted imbalances in covariates across groups.
Results: Based on 12 700 patients with high-risk PCa, statin alone or in combina-
tion with metformin was significantly associated with reduced all-cause mortality 
(Hazard Ratio [HR]: 0.89; 95% Confidence Interval [CI]: 0.83, 0.96; and HR: 0.75; 
95% CI, 0.67-0.83, respectively) and PCa mortality (HR, 0.80; 95% CI: 0.69, 0.92) 
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1 |  INTRODUCTION
Approximately 15% of patients diagnosed with prostate can-
cer (PCa) patients have high-risk PCa as defined by ≥T2c, 
or PSA ≥20, or Gleason Score ≥8.1 Patients with high-risk 
PCa have a significant chance of developing systemic or local 
recurrence and are at higher risk of death from the disease. 
Therefore, thus, tremendous attempts to further reduce PCa 
mortality are directed at these patients. The majority of pa-
tients with PCa who later develop lethal metastatic disease 
have high-risk localized disease at presentation, also empha-
sizing the importance of effective treatment strategies at this 
stage.2 Identifying or developing additional therapies with 
low toxicity and cost is important to improve longevity and 
quality of life of men diagnosed with high-risk PCa.
Evidence suggests that two widely prescribed drugs with 
established safety profiles, metformin and statins, have prom-
ising anti-cancer effects and are associated with lower mor-
tality in PCa patients.3,4 Several epidemiologic studies have 
investigated the effects of individual use of metformin and 
statins on PCa incidence and mortality.5-9 Recently, pre-clin-
ical data indicated a combination of metformin and statin 
was better than either drug alone in inhibiting primary tumor 
growth, metastasis to bone, and biochemical failure; human 
data on the joint effects of statins and metformin on PCa 
mortality are limited.10,11 Because the majority of metformin 
users also take statins12,13 some of the favorable outcomes ob-
served among metformin users might be derived from statins.
It is essential to distinguish the individual and joint effects 
of statins and metformin to further understand their potential 
synergistic role in cancer, explore alternative therapeutics for 
preventing PCa progression, and to inform future trial design. 
The primary objective of this study was to quantify the indi-
vidual and joint effects of metformin and statins on all-cause 
and PCa mortality, and to test the hypothesis that a combi-
nation of metformin and statin is associated with lower all-
cause and PCa mortality among high-risk patients. In order 
to understand the role of statins or metformin in an adjuvant 
setting, we specifically sought to quantify the individual and 
joint effects of statins and metformin in post-diagnostic set-
tings (ie, medications initiated after PCa diagnosis).
2 |  MATERIALS AND METHODS
2.1 | Data sources and study participants
We used data from the Surveillance, Epidemiology, and End 
Results (SEER-18) database linked with Medicare files. The 
SEER program covers about 28% of the US population, col-
lects information on newly diagnosed cancer patients living 
in predefined US geographical areas, with about 98% ascer-
tainment rate.14
Our study includes patients diagnosed with cancer through 
2011, and Part D data 2007-2012. To allow a 1-year window 
before or after cancer diagnosis for baseline assessment of 
comorbidities and use of prescriptions, we selected patients 
with high-risk PCa being diagnosed from January 2008 to 
December 2011 (Figures 1 and 2).
Primary PCa cases were identified using the International 
Classification of Disease for Oncology, Third Edition (ICD-
O-3) histology codes (https ://seer.cancer.gov/icd-o-3/). 
Patients were excluded if enrolled in health-care maintenance 
organizations, diagnosed at autopsy, missing a diagnosis date, 
or had a death date equal to or less than the diagnosis date. 
To ensure that Medicare claims were available for all partic-
ipants, we included patients who were continuously enrolled 
in Medicare Part A and B during the study period (January 
2007 to February 2014). To capture the potential drug ef-
fect up to 3 months before cancer diagnosis, we further re-
stricted our study to those who were continuously enrolled 
in Medicare Part D beginning at least 3 months prior cancer 
diagnosis until death or December 31, 2012, the last date of 
available Part D data. All patients were assigned into low-, 
Number: K07CA190541; Sidney Kimmel 
Foundation for Cancer Research, Grant/
Award Number: 5P30CA056036-18; 
Pennsylvania Department of Health, Grant/
Award Number: PA CURE Award SAP # 
4100077067
and 0.64; 95% CI, d 0.51-0.81, respectively. The effects were more pronounced in 
post-diagnostic users: combination use of metformin/statins was associated with a 
32% reduction in all-cause mortality (95% CI, 0.57-0.80), and 54% reduction in PCa 
mortality (95% CI, 0.30-0.69). No significant association of metformin alone was 
observed with either all-cause mortality or PCa mortality.
Conclusions: Statin use alone or in combination with metformin was associated with 
lower all-cause and PCa mortality among high-risk patients, particularly in post-di-
agnostic settings; further studies are warranted.
K E Y W O R D S
all-cause mortality, high-risk prostate cancer, metformin, population-based cohort, prostate-cancer 
mortality, statins, time-varying Cox proportional hazard models
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intermediate-, or high-risk groups based on D'Amico classi-
fication system.15 We selectively focused on high-risk PCa 
(T category ≥T2c or prostate specific antigen level ≥20 or 
Gleason score ≥8; equivalent to overall cancer stage ≥IIB), 
because evidence regarding statin effects are most consistent 
for advanced PCa.3 Moreover, because the follow-up time of 
this study was relatively short, precise estimates of PCa mor-
tality endpoints could be reached in high-risk patients only. 
To account for latency effects and minimize healthy user ef-
fect (statins are usually discontinued in individuals with short 
life expectancy), we further restricted our study to those 
who survived at least 6  months. The study was conducted 
in accordance with a SEER-Medicare data use agreement 
and approved by the Institutional Review Board at Rutgers 
University.
2.2 | Metformin and statin exposures
To determine metformin and statin exposures, Part D pre-
scription drug event files were used. These files include infor-
mation on drug name, dispensation dates, dosage, and days’ 
supply for each prescription. We defined post-diagnostic 
users as patients who had their first documented prescription 
F I G U R E  1  Selection of patients diagnosed with primary high-risk prostate cancer in SEER 2008-2011
123 578 prostate cancer patients ≥ 65 years of age 
reported to SEER in 2008 -2011 Excluding patients diagnosed at autopsy (N = 2507) and 
patients with different month of death in SEER and Medicare 
(N = 151)
120 920 prostate cancer patients with known diagnosis 
and death time Excluding patients who were not continuously enrolled in 
Medicare Part A and B during the study period  (N = 20 472), 
and patients who were not enrolled in Part D from 3 months 
before diagnosis to death or February 15, 2014 (N = 43 250)57 198 prostate cancer patients with continuous 
enrollment in Medicare Part A, B and D 
(N = 63 722)
(N = 2658)
13 745 high-risk prostate cancer patients (T category ≥ 
T2c or PSA level ≥ 20 or Gleason score ≥ 8)
Excluding patients who are not high-risk of prostate cancer 
(N = 43 453)
Excluding patients who survived less than for 6 months(N = 1045)
12 700 high risk prostate cancer patients survived at 
least for 6 months 
F I G U R E  2  Timeline of a patient's baseline status and exposure through the study. The follow-up starts on the date of prostate cancer 
diagnosis, January 15, 2008 (cohort entry date). The 1-yr look-back period for comorbidities, procedures, and use of prescription started on January 
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• Last date of study 
(February 15, 2014)
One year look-back 
window of baseline 
assessment for 
comorbidities, 
procedures, and use 
of prescription
Date of Part D 
available
January 01, 2007
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of study medication after the PCa diagnosis. Patients who 
had first documented prescription of study medication before 
the PCa diagnosis and continuously used the drug after di-
agnosis were considered pre-diagnostic users. Statins were 
categorized based on the following drug characteristics: li-
pophilic (atorvastatin, fluvastatin, lovastatin, and simvasta-
tin); hydrophilic (pravastatin and rosuvastatin); high potency 
(atorvastatin, rosuvastatin, and simvastatin); or low potency 
(fluvastatin, lovastatin, and pravastatin).16
2.3 | Assessment of covariates and 
study outcomes
Information was extracted on age, race, marital status, region, 
year of diagnosis, state buy-in (for individual with limited in-
come and resources, the state pays part or all of the patient's 
Medicare Part B premium or the person is in the Medicaid 
program), as well as contextual data on socioeconomic status 
including income and education. To avoid overestimating co-
morbidity as a result of PCa diagnosis, the Charlson score was 
based on diagnosis codes from 11 months prior to cancer di-
agnosis.17 Receipt of primary cancer therapy was ascertained 
within 1 year of cancer diagnosis,18 and the presence of second-
ary cancer therapy was ascertained if patients switched to other 
cancer therapies after a period of primary therapy.
The primary endpoints were all-cause and PCa mortality. 
Data on all-cause and PCa mortality were based on SEER re-
cords available through February 15, 2014 and December 15, 
2011, respectively (Figure 2). Causes of PCa death in the SEER 
record were based on the underlying causes of death in the 
death certificate, which had a high agreement (87%-92%) with 
medical record review.19 Patients were censored at death, last 
contact, or the last date of available data for endpoints.
2.4 | Statistical analyses
Descriptive statistics with Chi-square tests were used to esti-
mate the differences on demographic and clinical characteris-
tics. Propensity scores 20 were used to estimate the probability 
of one of the following four exclusive medication use catego-
ries: “ever used statin” (p1), “ever used metformin” (p2), “ever 
used both statin and metformin” (p3) and “none.” They were 
calculated based on patients’ sociodemographic characteristics, 
and comorbidities (Charlson Comorbidity Score, diabetes, obe-
sity/metabolic syndrome, and hyperlipidemia) using a general 
(polytomous) logistic regression model.21 To control pre-treat-
ment imbalances on observed variables, propensity scores p1, 
p2, and p3 were included as covariates in the statistical mod-
els for propensity score adjustment. Cox proportional hazards 
models (with competing causes of death) were used to estimate 
hazards ratios (HRs) and 95% confidence intervals (CIs).22,23
The association between metformin and/or statin use and 
all-cause and PCa mortality was evaluated by sequentially 
adding the following variables: (a) demographic character-
istics; (b) tumor characteristics; (c) treatment characteristics; 
(d) comorbidities, and (e) Charlson Comorbidity Score. We 
developed the final model by adjusting for cancer stage, pri-
mary cancer therapy (surgery, radiotherapy, androgen depri-
vation therapy [ADT]), secondary cancer therapy, salvage 
radiation, and propensity scores, as well as the variables that 
remained imbalanced after propensity score adjustment (ie, 
age, Charlson Score, diabetes, dyslipidemia, diabetes/IGT). 
Cancer stage were grouped based on five key components 
(T category, N category, M category, PSA level and Gleason 
core) using the American Joint Committee on Cancer TNM 
staging system. We included overall cancer stage instead 
of individual component to reduce a large number of vari-
ables in Cox models. For all of the models we considered, 
the proportional hazards assumption was evaluated using 
Schoenfeld residual plots.24 All analyses were two-tailed 
test based on α = 0.05 and conducted using SAS Version 9.4 
(SAS Institute).
2.5 | Sensitivity and subgroup analyses
According to the new National Comprehensive Cancer 
Network risk criteria,25 patients with a clinical stage of T2c 
were no longer considered to have high-risk PCa. Therefore, 
we performed a sensitivity analysis using the study population 
including all patients with clinical stage ≥T3a, or Gleason 
score ≥8, or PSA ≥20 ng/mL. To address potential healthy 
user effects and latency for analyses of post-diagnostic statin 
use, we restricted our study to those who survived at least for 
6 months. However, potential bias could result from exclud-
ing the sickest cases for analyses of pre-diagnostic statin use, 
we further performed a sensitivity analysis by including the 
patients with survival less than 6 months. Additionally, it is 
important to know whether the drug effect varies with patient 
characteristics, other cancer therapies received, or other prog-
nostic factors; therefore, we carried out multiple pre-planned 
sub-analyses by: (a) primary cancer therapy; (b) presence of 
secondary cancer therapy, suggesting that the patients have 
failed primary cancer therapy; (c) cancer stage and M catego-
ries; (d) statin name, type, and potency; and (e) presence of 
documented obesity or other major comorbidities.
3 |  RESULTS
3.1 | Baseline characteristics
The study cohort consisted of 12 700 high-risk PCa patients 
who were diagnosed between 2008 and 2011, and survived 
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at least for 6  months. The median age at diagnosis was 
74  years (quartiles: 70-80). During a median follow-up of 
42 months (quartiles: 26.4-57.6), 2182 (17.2%) patients died 
from any cause and 1078 (8.5%) died from prostate cancer. 
Most metformin users took statins (1911/2346 = 81%, Table 
1). Compared to those who did not use statins or metformin, 
users of metformin alone, statin alone, and their combination 
were significantly younger and more likely to have diabe-
tes, obesity or metabolic syndrome, and hyperlipidemia, and 
had a higher Charlson score with less advanced-stage cancer 
(Table 1).
3.2 | Survival outcomes
Median survival was 3.1  years with metformin, 3.6 with 
statins, and 3.9 with metformin plus statin, vs 3.1 years for 
those who did not use either drug. Based on Cox models, 
metformin plus statin (HR, 0.75; 95% CI, 0.67-0.83) and sta-
tin alone (HR, 0.89; 95% CI, 0.83-0.96) were significantly as-
sociated with a lower all-cause mortality, after adjusting for 
potential confounders (Table 2). With respect to PCa mor-
tality, metformin plus statin was associated with a 36% risk 
reduction (95% CI, 0.54-0.85), followed by statin alone (HR, 
0.80; 95% CI, 0.69-0.92) (Table 2). Metformin alone was 
relatively rare, and there was no significant association with 
all-cause mortality (HR, 0.89; 95% CI, 0.75-1.05) (Table 2), 
and PCa mortality (HR, 0.75; 95% CI, 0.53-1.05) (Table 2).
To provide insight about the potential impact in an ad-
juvant setting, we examined the differential effects among 
pre-diagnostic and post-diagnostic users. The effects of statin 
alone or combination of metformin and statin on both all-
cause and PCa mortality are more pronounced in post-diag-
nostic users. Among post-diagnostic users, statin alone was 
significantly associated with a 27% reduction in all-cause 
mortality (95% CI, 0.64-0.84) and a 42% reduction in PCa 
mortality, compared to those who did not use statins or met-
formin. Metformin plus statins was associated with a 32% 
reduction in all-cause mortality (95% CI, 0.57-0.80), and a 
54% reduction in PCa mortality (95% CI, 0.30-0.69) (Table 
2). Again, metformin alone did not show any significant ef-
fects on all-cause mortality and PCa mortality among either 
pre-diagnostic or post-diagnostic users (Table 2).
3.3 | Sensitivity and subgroup analyses
We first performed sensitivity analyses by using the study 
population including all patients with clinical stage ≥T3a, 
or Gleason score ≥8, or PSA ≥20  ng/mL. Similar HRs of 
all-causes and PCa mortality were observed for metformin 
and/or statin use (data not shown). Therefore all of the fol-
lowing subgroup analyses were performed using the study 
population that included all patients with clinical stage ≥T2c, 
or Gleason score ≥8, or PSA ≥20 ng/mL. We also performed 
sensitivity analyses by including the patients with survival 
less than 6 months, and a similar pattern of the results with 
even lower HRs were observed (data not shown).
To assess the impact of disease extent on observed drug 
effects, we stratified medication use by disease extent (ie, 
cancer stage, M categories), and found no significant ef-
fect modification for both all-cause and PCa mortality 
(Pinteraction > .05) (Table S1). Among patients with Stage IV 
PCa, data suggest there might be some synergistic effect be-
tween statin and metformin (HR, 0.93 for metformin alone, 
0.82 for statin alone, and 0.66 for metformin plus statin) al-
though this interaction did not reach statistical significance 
(Pinteraction = .18) (Table S1).
To assess the impact of existing health conditions on ob-
served drug effects, we carried out pre-planned sub-analyses 
by the status of diabetes, dyslipidemia, or obesity/metabolic 
syndrome. We found that diabetes and dyslipidemia signifi-
cantly modified the effects of statin alone or metformin plus 
statin on all-cause mortality (Pinteraction < .0001), but not on 
PCa mortality (Pinteraction  ≥  .05) (Table S2). No significant 
effect modification of obesity/metabolic syndrome was ob-
served for both all-cause and PCa mortality (Pinteraction > .05) 
(Table S2). To evaluate the effect modification of cancer 
treatment, we stratified by the status of primary and second-
ary cancer therapy as well as salvage radiation, we observed 
no evidence that they modified the effects of metformin and 
statins (Pinteraction > .05) (Tables S3 and S4). To account for 
the healthy user effects, we further stratified by Charlson 
score, and found no significant effect modification for both 
all-cause and PCa mortality (Pinteraction > .05) (Table S5).
Further pre-planned sub-analyses revealed that among 
statins, only lovastatin was not significantly associated with 
the reduction in PCa mortality (HR, 0.92; 95% CI, 0.76-1.12) 
(Table 3). The effects of lipophilic vs hydrophilic and high vs 
low potency statins were not statistically different (Table 3).
4 |  DISCUSSION
Both metformin and statins are individually associated with 
reduction in PCa mortality and the use of both medications 
together is common.3,4 To the best of our knowledge, this is 
the first major epidemiological study to quantify individual 
and joint effects of metformin and statin on all-cause and PCa 
mortality among high-risk PCa patients. We found that both 
statin alone and a combination of metformin and statin was 
significantly associated with reduced all-cause and PCa mor-
tality. The effect of combination use of metformin and sta-
tin was particularly substantial among post-diagnostic users 
with high-risk PCa (54% reduction in PCa mortality) despite 
the relatively short follow-up time. Based on the existing 
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T A B L E  1  Demographic, clinical, and comorbid characteristics
Variables
















65-69 3123 (25) 1117 (24) 122 (28)* 1328 (23)** 556 (29)**    
70-79 6344 (50) 2150 (47) 218 (50) 2938 (51) 1038 (54)    
80+ 3233 (25) 1301 (28) 95 (22) 1520 (26) 317 (17)    
Marital status <.01 .98
No 3307 (26) 1300 (28) 117 (27) 1436 (25)** 454 (24)**    
Yes 7806 (61) 2696 (59) 258 (59) 3653 (63) 1199 (63)    
Unknown 1587 (12) 572 (13) 60 (14) 697 (12) 258 (14)    
Race <.01 .96
White 9805 (77) 3495 (77) 307 (71)* 4597 (79)** 1406 (74)**    
Black 1652 (13) 678 (15) 77 (18) 619 (11) 278 (15)    
Others 1243 (10) 395 (9) 51 (12) 570 (10) 227 (12)    
Region <.01 .72
Northeast 1651 (13) 569 (12) 60 (14) 781 (14)* 241 (13)    
South 2625 (21) 970 (21) 113 (26) 1123 (19) 419 (22)    
North central 1146 (9) 445 (10) 37 (9) 501 (9) 163 (9)    
West 7278 (57) 2584 (57) 225 (52) 3381 (58) 1088 (57)    
Educationa <.01 .73
>92% 4079 (32) 1451 (34) 102 (23)** 1997 (35)** 529 (28)**    
80%-92% 4556 (36) 1656 (36) 173 (40) 2025 (35) 702 (37)    
< 80% 3434 (27) 1249 (27) 134 (31) 1457 (25) 594 (32)    
Unknown 631 (5) 212 (5) 26 (6) 307 (5) 86 (5)    
Median income <.01 .86
≤$45 000 3833 (30) 1459 (32) 155 (36)* 1603 (28)** 616 (32)    
$45000-$70 000 4238 (33) 1504 (33) 154 (35) 1908 (33) 672 (35)    
>$70 000 4021 (32) 1401 (31) 101 (23) 1980 (34) 539 (28)    
Unknown 608 (5) 204 (4) 25 (6) 295 (5) 84 (4)    
Year of diagnosis <.01 .97
2008 4028 (32) 1407 (31) 142 (33) 1829 (32)* 650 (34)*    
2009 3734 (29) 1298 (28) 116 (27) 1771 (31) 549 (29)    
2010 2529 (20) 939 (21) 82 (19) 1127 (19) 381 (20)    
2011 2409 (19) 924 (20) 95 (22) 1059 (19) 331 (17)    
State buy-inb <.01 .54
No 9542 (75) 3407 (75) 300 (69)* 4503 (78)** 1332 (70)**    
Yes 3158 (25) 1161 (25) 135 (31) 1283 (22) 579 (30)    
Charlson scorec <.01 .03
0 7970 (63) 3426 (75) 207 (48)** 3568 (62)** 769 (40)**    
1 2004 (16) 567 (12) 114 (26) 926 (16) 397 (21)    
2+ 2726 (21) 575 (13) 114 (26) 1292 (22) 745 (39)    
Diabetes <.01 <.01
No 6928 (55) 3244 (71) 65 (15)** 3375 (58)** 244 (13)**    
(Continues)
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Yes 5772 (45) 1324 (29) 370 (85) 2411 (42) 1667 (87)    
Obesity/metabolic syndrome <.01 .01
No 10 806 (85) 4123 (90) 356 (82)** 4924 (85)** 1403 (73)**    
Yes 1894 (15) 445 (10) 79 (18) 862 (15) 508 (27)    
Hyperlipidemia           <.01 <.01
No 4316 (34) 2653 (58) 187 (43)** 1138 (20)** 338 (18)**    
Yes 8384 (66) 1915 (42) 248 (57) 4648 (80) 1576 (82)    
Cancer stage <.01 NC
IIB 8546 (67) 2902 (64) 270 (62) 4023 (70)** 1351 (71)**    
III 1259 (10) 457 (10) 53 (12) 559 (10) 190 (10)    
IV 2895 (23) 1209 (26) 112 (26) 1204 (21) 370 (19)    
M categories <.01 NC
M0 9646 (76) 3281 (72) 309 (71) 4542 (78)** 1513 (79)**    
M1 2412 (19) 1066 (23) 101 (22) 942 (16) 303 (16)    
Unknown 642 (5) 221 (5) 25 (5) 302 (5) 95 (5)    
Lymph notes <.01 NC
No 10 283 (81) 3598 (79)** 336 (77)** 4773 (82)** 1576 (82)**    
Yes 971 (8) 390 (9) 44 (10) 407 (7) 130 (7)    
Missing 1446 (11) 580 (13) 55 (13) 606 (10) 205 (11)    
Androgen deprivation therapyd <.01 NC
No 8279 (65) 2980 (65) 250 (57)** 3829 (66) 1220 (64)    
Yes 4421 (35) 1588 (35) 185 (43) 1957 (34) 691 (36)    
Radiation therapyd <.01 NC
No 9535 (75) 3581 (78) 316 (73)** 4278 (74)** 1360 (71)**    
Yes 3165 (25) 987 (22) 119 (27) 1508 (26) 551 (29)    
Chemotherapyd .54 NC
No 12 176 (96) 4374 (96) 418 (96) 5561 (96) 1823 (95)    
Yes 524 (4) 194 (4) 17 (4) 225 (4) 88 (5)    
Surgeryd <.01 NC
No 10 890 (86) 4000 (88) 389 (89) 4873 (84)** 1628 (85)**    
Yes 1810 (14) 568 (12) 46 (11) 913 (16) 183 (15)    
Salvage radiation .08 NC
No 12 356 (97) 4458 (98) 419 (96) 5612 (97) 1867 (98)    
Yes 344 (3) 110 (2) 16 (4) 174 (3) 44 (2)    
Secondary therapy <.01 NC
No 9297 (73) 3457 (76)** 304 (70)** 4211 (73)** 1325 (69)**    
Yes 3403 (27) 1111 (24) 131 (30) 1575 (27) 586 (31)    
Gleason categories <.01 .17
<8 2293 (18) 788 (17) 57 (13)** 1082 (19) 366 (19)    
8 2322 (18) 743 (16) 82 (19) 1128 (19) 369 (19)    
>8 2042 (16) 687 (15) 74 (17) 943 (16) 338 (18)    
T A B L E  1  (Continued)
(Continues)
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evidence, a well-designed clinical trial is warranted to inves-
tigate the roles of statins and combination statins/metformin 
to reduce the mortality of PCa.
Several epidemiological studies have previously inves-
tigated the association between statin use and all-cause or 
PCa mortality, with encouraging though mixed findings. We 
observed that use of statin alone or in combination with met-
formin was significantly associated with reduced all-cause and 
PCa mortality. This finding is comparable with the results from 
several recent publications. For example, a large retrospective 
cohort study with 249.986 Saskatchewan Men aged ≥40 years 
reported a substantial protective association between statin use 
and PCa mortality (HR, 0.73; 95% CI, 0.66-0.81).26 Wu et al 
reported that compare to non-users, statin use was associated 
with significant reductions in all-cause mortality (HR, 0.75; 
95% CI, 0.68-0.82) and PCa mortality (HR, 0.77; 95% CI, 
0.69-0.86) in locally advanced and metastatic PCa patients.27 
In addition, using national Veterans Health Administration 
Variables















Missing 6043 (48) 2350 (51) 222 (51) 2633 (46) 838 (44)    
Abbreviations: NC, not calculated; PSA, prostate-specific antigen.
aReflecting a percentage of high school education. 
bIndicating that the state pays part or all of the patient's medicare part B premium or the person is in the Medicaid program. 
c1 year to 1 month before cancer diagnosis. 
dWithin 1 year of cancer diagnosis. 
eReflects differences between groups after adjusting for propensity score for metformin, statin, and dual users. 
*P < 0.05, compared to neither users. 
**P < 0.01, compared to neither users. 
T A B L E  1  (Continued)
T A B L E  2  Hazard ratios (HRs) of all-causes and PCa mortality for metformin and/or statin use in the whole population or pre- and post-
diagnostic users
Category










No metformin/no statin 1.0 1.0 1.0 1.0
Metformin alone 1.00 (0.85-1.17) 0.89 (0.75-1.05) 0.71 (0.51-1.00) 0.75 (0.53-1.05)
Statin alone 0.81 (0.75-0.86)** 0.89 (0.83-0.96)** 0.63 (0.55-0.72)** 0.80 (0.69-0.92)**
Metformin+statin 0.69 (0.63-0.76)** 0.75 (0.67-0.83)** 0.45 (0.36-0.55)** 0.64 (0.51-0.81)**
Pre-diagnostic users
No metformin/no statin 1.0 1.0 1.0 1.0
Metformin alone 1.08 (0.89-1.31) 0.91 (0.75-1.11) 0.75 (0.50-1.11) 0.76 (0.50-1.13)
Statin alone 0.87 (0.82-0.94)** 0.94 (0.87-1.02) 0.69 (0.61-0.79)** 0.84 (0.73-0.98)*
Metformin+statin 0.77 (0.69-0.86)** 0.82 (0.72-0.92)** 0.52 (0.41-0.66)** 0.73 (0.56-0.95)**
Post-diagnostic users
No metformin/no statin 1.0 1.0 1.0 1.0
Metformin alone 0.85 (0.64-1.13) 0.89 (0.67-1.19) 0.65 (0.36-1.18) 0.73 (0.39-1.35)
Statin alone 0.57 (0.50-0.64)** 0.73 (0.64-0.84)** 0.38 (0.28-0.51)** 0.58 (0.43-0.78)**
Metformin+statin 0.56 (0.48-0.66)** 0.68 (0.57-0.80)** 0.31 (0.21-0.47)** 0.46 (0.30-0.69)**
aAdjusted for cancer stage, ADT, radiation therapy, surgery, salvage radiation, secondary cancer therapy, propensity scores, and imbalanced variables after propensity 
scores adjustment. 
*P < .05, compared to controls. 
**P < .01, compared to controls. 
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database, Anderson-Carter et al identified 87 346 PCa patients 
on ADT and found that statin use was an independent predictor 
of improved overall survival (HR, 0.66; 95% CI, 0.63-0.68) 
and PCa specific survival (HR, 0.56; 95% CI, 0.53-0.60).28 
However, several prior studies did not show an association 
between this medication and prostate cancer mortality.29-31 
This discrepancy may be due to the different study population 
across these studies, indicating the findings may apply to clin-
ical heterogeneous of PCa patients. Only two studies aimed 
to examine the combination effect of metformin and statin on 
prostate cancer outcomes.11,32 One study showed the combi-
nation leads to synergistic effects to lower risk of biochemical 
recurrence after radical prostatectomy,11 but the other showed 
negative results.32 To the best of our knowledge, this is the first 
study distinguishing the individual and joint effects of statins 
and metformin on all-cause and PCa mortality in high-risk 
PCa patients.
We also found that post-diagnostic statin use was asso-
ciated with lower PCa mortality compared to pre-diagnostic 
statin use. A recent population-based cohort study consisting 
of a general male population of Finland participating in the 
Finnish Randomized Study for PCa Screening showed that 
post-diagnosis statin use but not pre-diagnostic statin use was 
significantly associated with a decreased risk of PCa death.33 
Additionally, Larsen et al reported that post-diagnostic statin 
use was associated with a 19% reduction in all-cause mor-
tality and 17% reduction in PCa mortality among 31  790 
Danish PaCA patients. 9 However, these studies did not focus 
on high-risk patients and did not adjust for metformin effect. 
Our finding differs from a published study by Yu et al, which 
found that decreased risk of PCa mortality was more pro-
nounced when patients used statins both before and after can-
cer diagnosis.34 The discrepancy might stem from differences 
in study populations and data sources (the study by Yu et al 
did not include cancer stage, Gleason grade, or PSA in most 
of the patients).
Our study also revealed that men took atorvastatin, 
pravastatin, or rosuvastatin, but not lovastatin demonstrated 
a significant reduction in PCa mortality compared with 
non-users, which is consistent with the findings from a re-
cent population-based cohort study using Taiwan National 
Health Insurance Research Data.27 We have only one pa-
tient with fluvastatin and no patient with pitavastatin in our 
study, therefore no statistic survival analysis is available for 
the fluvastatin and with pitavastatin. It has been shown that 
that atorvastatin, pravastatin, and rosuvastatin are more ef-
fective at lowering triglycerides and low-density lipoprotein 
cholesterol and raising high-density lipoprotein cholesterol 
than other statins in patient with hypercholesterolemia.35,36 
Interestingly, use of atorvastatin was associated with a re-
duction in PCa mortality (HR, 0.76; 95% CI, 0.63-0.91), 
which is consistent with a recent study demonstrating that 
men on atorvastatin had a longer median time to progres-
sion on androgen deprivation therapy compared to non-us-
ers (27.5 vs 17.4 months, P =  .0005).37 The in vitro study 
further demonstrated that atorvastatin competitively reduced 
dehydroepiandrosterone sulfate uptake and thus, effectively 
decreased the available intratumoral androgen pool, affording 
a plausible mechanism to support the clinical observation.37 
Although the exact mechanisms remain unknown, it is worth 
Category







Atorvastatin 350/5003 0.61 (0.52-0.73)** 0.76 (0.63-0.91)**
Lovastatin 78/5003 0.96 (0.79-1.15) 0.92 (0.76-1.12)
Pravastatin 282/5003 0.53 (0.41-0.69)** 0.68 (0.52-0.89)**
Rosuvastatin 120/5003 0.51 (0.36-0.70)** 0.71 (0.50-0.99)*
Simvastatin 865/5003 0.73 (0.64-0.83)** 0.87 (0.75-0.99)*
Typeb
Lipophilic 1165/5003 0.68 (0.60-0.76)** 0.85 (0.74-0.97)*
Hydrophilic 385/5003 0.50 (0.40-0.62)** 0.69 (0.55-0.85)**
Potencyb
Low 353/5003 0.61 (0.54-0.69)** 0.83 (0.72-0.95)**
High 1185/5003 0.79 (0.68-0.93)** 0.86 (0.73-1.01)
aAdjusted for cancer stage, ADT, radiation therapy, surgery, salvage radiation, secondary cancer therapy, 
propensity scores, imbalanced variables after propensity scores adjustment, and metformin use. 
bCategories are not mutually exclusive for these variables. 
cOne patient with fluvastatin were excluded from the analysis. 
*P < .05, compared to non-statin users. 
**P < .01, compared to non-statin users. 
T A B L E  3  Hazard ratios for the 
association between statin use (name, type, 
and potency) and PCa mortality among post-
diagnostic users
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noting that atorvastatin exhibits one of the most potent lip-
id-lowering effects per dose of any statin, one of the greatest 
bioavailability, and one of the longest half-lives.38
Our findings likely apply to most PCa patients because 
of the broad representation of various racial/ethnic groups 
in this study. The findings may be limited; however, by 
the data sources. The SEER-Medicare database contains 
limited data on men under age 65. Given that the majority 
of PCa is diagnosed among patients who are over age 65, 
our findings likely apply to most PCa patients. It is pos-
sible that some of the non-users might have used statins 
or metformin prior to 2007, the earliest year of available 
Part D data. It is worth noting that post-diagnostic users 
are much less likely to be affected by prevalent user effect 
because we have more than one year of claims to verify 
the use of metformin or statins. Therefore, it is unlikely 
the misclassification could explain away the large effect 
observed in post-diagnostic patients. While immortal time 
bias might occur among post-diagnostic users because they 
need to live long enough to start medications. However, 
we have used the following approaches to minimize its ef-
fects. First, we restricted to the study population to those 
who survived at least 6 months so that the probability of 
initiating metformin or statin after PCa diagnosis is about 
the same across groups. Second, we made adjustment to 
propensity scores, which estimate the probability of being 
one of four exclusive treatment groups, to account for the 
confounding effects associated with various patient char-
acteristics or disease status. Lastly, we aligned their fol-
low-up time according to time origin for PCa diagnosis so 
that comparisons are being made across persons at equal 
distance from time origin. SEER-Medicare files also lack 
data on some important confounding variables, including 
body mass index, smoking, family history of cancer, or use 
of nonsteroidal anti-inflammatory drugs, but subgroup and 
sensitivity analyses showed that our results are relatively 
robust (Tables S1-S5).39 It is worth noting that dual users 
of metformin and statin had higher comorbidity scores at 
the baseline vs non-users and this might have led to under-
estimated treatment benefits. Finally, the impact of the drug 
exposure may not be fully captured and limited sample size 
of metformin monotherapy users. However, by focusing on 
high-risk patients, our study showed clinically meaningful 
differences in PCa mortality in various sub-groups.
5 |  CONCLUSION
Our data demonstrated that statin alone is associated with re-
duced all-cause and PCa mortality, and combination of met-
formin and statin holds great promise for reducing all-cause or 
PCa mortality among patients with high-risk PCa, particularly 
in post-diagnostic settings. Further sub-analyses revealed that 
all brand of statins, except lovastatin, were significantly asso-
ciated with the reduction in PCa mortality, and the effects of 
lipophilic vs hydrophilic and high vs low potency statins were 
not statistically different. The data presented in this paper pro-
vide crucial insight for the design of future randomized clini-
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